<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00766545</url>
  </required_header>
  <id_info>
    <org_study_id>021-91-001</org_study_id>
    <nct_id>NCT00766545</nct_id>
  </id_info>
  <brief_title>Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction.</brief_title>
  <acronym>CSPS</acronym>
  <official_title>Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The multi-center, double-blind, placebo-controlled, randomized, group-comparison study was
      designated to assess the long-term safety and efficacy of the antiplatelet drug cilostazol in
      preventing the recurrence of cerebral infarction in patients who had suffered a cerebral
      infarction 1 to 6 months prior to entering the trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1992</start_date>
  <completion_date type="Actual">March 1997</completion_date>
  <primary_completion_date type="Actual">March 1997</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of cerebral infarction</measure>
    <time_frame>any time</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral infarction or myocardial infarction, Cerebral infarction, intracranial hemorrhage, or TIA, Cerebral infarction, intracranial hemorrhage, myocardial infarction, or vascular death, All vascular events, vascular death, and Death from any cause</measure>
    <time_frame>any time</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1095</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol oral tablet 100 mg, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo of cilostazol, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>oral tablet 100 mg, twice daily, over 1 year</description>
    <arm_group_label>cilostazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo of cilostazol</intervention_name>
    <description>oral tablet, 0 mg twice daily, over 1 year</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Prior cerebral infarction Onset at 1 to 6 months before randomization

          2. CT or MRI detection of responsible site

          3. Without serious complications (malignant tumor, liver cirrhosis, renal failure, or
             heart failure)

        Exclusion Criteria:

          1. History of intracranial hemorrhage

          2. Possibility of cardiogenic cerebral embolism in the past or future All patients with
             any of the following complications were excluded: mitral valve stenosis, prosthetic
             valve, endocarditis, myocardial infarction within 6 weeks after onset, ventricular
             aneurysm, intraventricular or intraatrial blood clots, mitral valve prolapsed (age
             under 45 years old, lacking other causes for cerebral embolism induction), atrial
             fibrillation, sick sinus syndrome, idiopathic cardiomyopathy

          3. Severe cerebral deficits rendering the patient bed-ridden, totally dependent, or
             demented

          4. Contraindications to the study drug Hemostatic disorders or systemic bleeding Pregnant
             or possibly pregnant women, or nursing mothers

          5. Requirement for nonstudy antiplatelet drugs, anticoagulant drugs, or fibrinolytic
             drugs for another disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Kanto area</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2008</study_first_posted>
  <last_update_submitted>January 8, 2009</last_update_submitted>
  <last_update_submitted_qc>January 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

